Exclusive: Sudo Biosciences secures $116M to start trials of its oral and topical TYK2 candidates December 20, 2023 Read More
BMS was first but startup Sudo Bio aims to be best at blocking key autoimmune target October 2, 2022 Read More
Bristol Myers got the first TYK2 approval. Frazier’s new biotech Sudo hopes to get many more September 28, 2022 Read More
/ News
/ News